Skip to content

Adis in touch

A blog from Adis, a leading global provider of drug information.

Recent Posts

  • Call for Papers – Drug Safety
  • World Drug Safety Congress Americas 2020: my first virtual conference experience
  • COVID breaks the chain
  • COVID causes chaos and special situations
  • Call for Papers – The Patient

Recent Comments

Pauline McWilliams on Reactions Weekly: Introducing…
Louise Grannell on Reactions Weekly: Introducing…
Chris Sampson’s jour… on Call for Papers: Themed Issue…
brent on Is the Search for a Cure for A…
Dr Paul Tappenden as… on Call for Papers: Themed Issue…

Archives

  • January 2021
  • October 2020
  • July 2020
  • June 2020
  • March 2020
  • February 2020
  • January 2020
  • October 2019
  • July 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • December 2018
  • November 2018
  • October 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • April 2016
  • October 2015
  • July 2015
  • June 2015
  • February 2015
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • May 2014
  • March 2014
  • January 2014
  • October 2013
  • July 2013
  • January 2012

Categories

  • Adis (91)
  • Adis Journals (98)
  • Adis Newsletters (1)
  • Adis Pharmacovigilance (33)
  • AdisInsight (98)
  • Uncategorized (3)

Tag: Negative recommendation

Dupilumab (Dupixent®): CADTH Publishes Negative Recommendation for Reimbursement in Canada

Dupilumab (Dupixent®): CADTH Publishes Negative Recommendation for Reimbursement in Canada

In July 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended not to reimburse dupilumab.[1] Continue reading “Dupilumab (Dupixent®): CADTH Publishes Negative Recommendation for Reimbursement in Canada” →

By Wendy McNeelyin Adis, Adis Journals, AdisInsightJuly 17, 2018200 WordsLeave a comment
Powered by WordPress.com.